Get access

AUGMENTATION OF FLUOXETINE WITH LOVASTATIN FOR TREATING MAJOR DEPRESSIVE DISORDER, A RANDOMIZED DOUBLE-BLIND PLACEBO CONTROLLED-CLINICAL TRIAL

Authors

  • Ahmad Ghanizadeh M.D.,

    Corresponding author
    1. Department of Psychiatry, Research Center for Psychiatry and Behavioral Sciences, Hafez Hospital, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
    • Correspondence to: Ahmad Ghanizadeh, Department of Psychiatry, Research Center for Psychiatry and Behavioral Sciences, Hafez Hospital, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. E-mail: ghanizad@sina.tums.ac.ir

    Search for more papers by this author
  • Arvin Hedayati M.D.

    1. Department of Psychiatry, School of Medicine, Fasa University of Medical Sciences, Fasa, Iran
    Search for more papers by this author

  • The trial was registered at the Iranian Clinical Trials Registry (http://www.irct.ir; IRCT ID: IRCT201304203930N22).

Abstract

Backgrounds

There are contradictory evidence about the effect of statins on depression. This 6-week-randomized placebo-controlled clinical trial assessed the efficacy and safety of lovastatin as an adjuvant agent for treating major depressive disorder (MDD).

Methods

The participants were 68 patients with MDD according to DSM-IV diagnostic criteria. The sample was randomly allocated into fluoxetine (up to 40 mg/day) plus lovastatin (30 mg/day) group or fluoxetine plus placebo group. Hamilton Depression Rating scale was used to measure depression score at baseline, week 2, and week 6.

Results

Both groups showed a significant decrease of depression score on the Hamilton Depression scale. However, the treatment group decreased depression score more than placebo group [12.8(6.3) vs. 8.2(4.0), t = 3.4, df = 60, P < .001]. Any serious adverse effect was not found.

Discussion

These results suggest that lovastatin as an adjuvant treatment may be effective for treating patients with MDD.

Ancillary